Please assess the completion status of the following clinical trial:

Trial Title: A Hepatitis B Vaccine Challenge Study After Previous Vaxelis® Vaccination (V419-013)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Is healthy (based on a review of medical history and targeted physical examination) based on the clinical judgment of the investigator.~* Has participated in Protocol V419-007 and received a 3 + 1 Vaxelis® schedule or participated in Protocol V419-008 and received a 2 + 1 Vaxelis® schedule.~* The participant (or legally acceptable representative if applicable) provides written informed consent/assent for the study.~Exclusion Criteria:~* Has a history of diagnosis (clinical, serological, or microbiological) of HBV infection.~* Has a known or suspected impairment of immunological function (e.g., human immunodeficiency virus (HIV), splenectomy).~* Has a known hypersensitivity to any component of the study vaccine.~* Has a known or suspected blood dyscrasias, leukemia, lymphomas of any type or other malignant neoplasms affecting the haematopoietic and lymphatic system.~* Has a bleeding disorder contraindicating intramuscular vaccinations.~* Has received any hepatitis B vaccine after participation in Protocol V419-007 or V419-008.~* Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 10 Years
- Healthy Volunteers: t

Study Arms:
- HBVAXPRO™ (Type: EXPERIMENTAL): Healthy children vaccinated approximately 8-9 years previously with a 2- or 3-dose infant series and toddler dose of Vaxelis® who will receive a single dose of Hepatitis B vaccine challenge (HBVAXPRO™).

Based on this trial design, predict the completion outcome and termination type (if applicable).